Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding ...

The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic factors.

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

Ovarian cancer remains the leading cause of death among cancers affecting the female reproductive system, largely because ...

A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, ...

Turning pain into purpose is the aim of a Northland ovarian cancer patient, who hopes a song about her cancer fight will ...